Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBT Margin (2016 - 2025)

Historic EBT Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2025 value amounting to 546.18%.

  • Agios Pharmaceuticals' EBT Margin rose 4361100.0% to 546.18% in Q4 2025 from the same period last year, while for Dec 2025 it was 769.18%, marking a year-over-year decrease of 27275200.0%. This contributed to the annual value of 765.89% for FY2025, which is 27330400.0% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its EBT Margin stood at 546.18% for Q4 2025, which was up 4361100.0% from 803.05% recorded in Q3 2025.
  • Agios Pharmaceuticals' EBT Margin's 5-year high stood at 11167.28% during Q3 2024, with a 5-year trough of 12073.44% in Q1 2022.
  • Over the past 4 years, Agios Pharmaceuticals' median EBT Margin value was 1184.15% (recorded in 2023), while the average stood at 1187.98%.
  • In the last 5 years, Agios Pharmaceuticals' EBT Margin skyrocketed by 124015600bps in 2024 and then tumbled by -119703300bps in 2025.
  • Quarter analysis of 4 years shows Agios Pharmaceuticals' EBT Margin stood at 2150.44% in 2022, then soared by 37bps to 1350.7% in 2023, then grew by 27bps to 982.28% in 2024, then surged by 44bps to 546.18% in 2025.
  • Its EBT Margin stands at 546.18% for Q4 2025, versus 803.05% for Q3 2025 and 903.6% for Q2 2025.